5551 - 5560 of 8826 Results
Title
Year
-
OPENTitle: Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trialJournal Name: eBioMedicinePublisher: Elsevier BVVol: 80Issue #:Start Page: 104021End Page: 104021Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104021Best OA location URL: http://www.thelancet.com/article/S2352396422002055/pdfCitation Count: 81
-
OPENTitle: Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiologyJournal Name: eBioMedicinePublisher: Elsevier BVVol: 85Issue #:Start Page: 104290End Page: 104290Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104290Best OA location URL: http://www.thelancet.com/article/S2352396422004728/pdfCitation Count: 31
-
OPENTitle: Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose AdjustmentJournal Name: European Medical JournalPublisher: European Medical GroupVol:Issue #:Start Page: 20End Page: 27Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.33590/emj/10022165Best OA location URL: https://www.emjreviews.com/wp-content/uploads/2022/12/Tailoring-Motor-Fluctuation-Treatment-Beyond-Levodopa-Dose-Adjustment-1.pdfCitation Count: 1
-
OPENTitle: Botulinum Toxin in the Treatment of Cervical Dystonia: Evidence-Based ReviewJournal Name: DystoniaPublisher: Frontiers Media SAVol: 1Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/dyst.2022.10655Best OA location URL: https://www.frontierspartnerships.org/articles/10.3389/dyst.2022.10655/pdfCitation Count: 7
-
OPENTitle: Tele-Yoga for the Management of Cervical Dystonia: A Safety and Feasibility TrialJournal Name: DystoniaPublisher: Frontiers Media SAVol: 1Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/dyst.2021.10015Best OA location URL: https://www.frontierspartnerships.org/articles/10.3389/dyst.2021.10015/pdfCitation Count: 0
-
OPENTitle: The Role of Alpha-Synuclein Autoantibodies in the Induction of Brain Inflammation and Neurodegeneration in Aged HumansJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page: 72End Page: 75Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2022.902191Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnagi.2022.902191/pdfCitation Count: 8
- Autoradiographic labelling of 5-HT3 receptors in the hemi-parkinsonian rat brain2021RESTRICTEDTitle: Autoradiographic labelling of 5-HT3 receptors in the hemi-parkinsonian rat brainJournal Name: Neuroscience ResearchPublisher: Elsevier BVVol: 177Issue #:Start Page: 135End Page: 144Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neures.2021.12.004Citation Count: 3
- Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursors2022RESTRICTEDTitle: Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursorsJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S88End Page: S89Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00209-8Citation Count: 0
- Alternative protective group strategy for the radiosynthesis of Flortaucipir 18F2022RESTRICTEDTitle: Alternative protective group strategy for the radiosynthesis of Flortaucipir 18FJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S88End Page: S88Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00208-6Citation Count: 0
- Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synuclein2022RESTRICTEDTitle: Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synucleinJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S87End Page: S88Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00207-4Citation Count: 0